0000950170-24-081628.txt : 20240703
0000950170-24-081628.hdr.sgml : 20240703
20240703171334
ACCESSION NUMBER: 0000950170-24-081628
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240701
FILED AS OF DATE: 20240703
DATE AS OF CHANGE: 20240703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Guyer William
CENTRAL INDEX KEY: 0001879013
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 241100907
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2024-07-01
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001879013
Guyer William
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
Chief Development Officer
true
Common Stock
2024-07-01
4
M
false
10000
21.65
A
16039
D
Common Stock
2024-07-01
4
S
false
10000
32.49
D
6039
D
Stock option (right to buy)
21.65
2024-07-01
4
M
false
10000
0
D
2031-09-01
Common Stock
10000
490000
D
Includes 478 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023 and 609 shares underlying unvested restricted stock units granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
Shares subject to the stock option vested and became exercisable with respect to 25% of the shares on the first anniversary of August 16, 2021 (the "Vesting Commencement Date") with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.
2024-07-03